Home > Journals > The Journal of Cardiovascular Surgery > Past Issues > The Journal of Cardiovascular Surgery 2020 October;61(5) > The Journal of Cardiovascular Surgery 2020 October;61(5):626-31



Publishing options
To subscribe
Submit an article
Recommend to your librarian


Publication history
Cite this article as



The Journal of Cardiovascular Surgery 2020 October;61(5):626-31

DOI: 10.23736/S0021-9509.20.07968-9


language: English

Evidence for treatment of lower limb in-stent restenosis with drug eluting balloons

Brian H. LI 1, Yiu C. CHAN 2 , Stephen W. CHENG 2

1 School of Medicine, Kings College Hospital, London, UK; 2 Division of Vascular and Endovascular Surgery, Department of Surgery, Queen Mary Hospital, University of Hong Kong Medical Centre, Hong Kong, China

INTRODUCTION: Restenosis by myointimal hyperplasia after peripheral arterial angioplasty or stenting often limits long term patency. Drug-eluting balloons (DEBs) which inhibit the proliferation of neo-intimal growth of vascular smooth muscle cells may prevent restenosis. The aim of this paper was to examine the evidence in published literature on the use of DEBs in the treatment of peripheral arterial in-stent restenosis (ISR).
EVIDENCE ACQUISITION: A systematic literature review was undertaken of all published literature on the treatment of peripheral ISR with drug eluting balloon using Medline and cross-referenced. All published papers on the use of DEBs in peripheral arterial disease (PAD) were used. Cochrane Central Register of Controlled Trials and electronic databases were also searched for on-going studies.
EVIDENCE SYNTHESIS: There were no level 1 or 2 evidence published on this subject. The number of high-quality publications is few, and consequently a sufficient analysis is not possible. Recently data from non-randomized cohort studies showed encouraging results with DEB as treatment modality for ISR, whether used alone or as combined strategies.
CONCLUSIONS: Evidence from the published literature suggests that DEBs are safe in preventing peripheral ISR. Despite strong corporate pressure for the use of DEBs, there is only circumstantial evidence that this is a useful modality for ISR. Results from on-going studies may allow further meta-analysis for efficiency and cost-effectiveness.

KEY WORDS: Peripheral arterial disease; Angioplasty; Stents; Coronary restenosis

top of page